Withdrawal of post- marketing authorisation application for atezolizumab (Tecentriq)

The application for combination treatment with platinum-based chemotherapy as a first line treatment for advanced/metastatic urothelial cancer was withdrawn because a positive benefit-risk balance could not be determined based on the data provided.

European Medicines Agency